Harpoon Therapeutics, Inc. (NASDAQ:HARP) Receives $24.75 Average Price Target from Brokerages
Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages […]
More Stories
6 Best Analytics Agencies in 2026 to Level Up Your Data Strategy
What do businesses do? Build and innovate from raw and scratch, right? But creation generates its own new raw material,...
Dalton Gomez Net Worth: How Rich Is Ariana Grande’s Ex-Husband?
He became popular following his affair with Ariana Grande. Even before he got into a relationship with Ariana, he was...
Trump Admin Aims to Create Family-Friendly Airports With Healthier Foods, Exercise Areas
By Jill McLaughlin The Trump administration is ready to spend $1 billion to create healthier food options, private breastfeeding pods,...
Trump Tells Xi US Will Ship Nvidia H200 Chips to ‘Approved Customers’ in China
By Catherine Yang President Donald Trump announced on Truth Social on Dec. 8 that he told Chinese Communist Party (CCP)...
Trump Announces $12 Billion Farm Aid Program
By Jacob Burg President Donald Trump on Dec. 8 unveiled a $12 billion economic assistance package for farmers. The Trump...
Paramount Launches $108.4 Billion Hostile Bid to Buy Warner Bros.
By Andrew Moran In a last-ditch effort to acquire the Warner Bros. entertainment empire, Paramount Skydance has launched a hostile...